EGFR and non-small cell lung carcinoma: Since the discovery that NSCLC is driven by activating mutations in EGFR, EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have been effectively utilized in clinical treatment [25].